Rigel Pharmaceuticals | RIGL - Дебиторская задолженность





Дебиторская задолженность Изменить Дата
Agenus USD 22.34M 107K 2026-03
Amgen USD 10.23B 1.09B 2026-06
Anika Therapeutics USD 29.33M 661K 2025-12
Arrowhead Research USD 8.56M 7.13M 2026-06
AstraZeneca USD 18.86B 972M 2026-06
BioMarin Pharmaceutical USD 1.06B 157.13M 2026-06
Bristol-Myers Squibb USD 13.83B 535M 2026-06
Celldex Therapeutics USD 230K 0 2026-06
Daiichi Sankyo JPY 676.92B 19.03B 2026-06
Eli Lilly USD 23.48B 2.3B 2026-06
Halozyme Therapeutics USD 453.33M 4.66M 2026-06
Heron Therapeutics USD 89.59M 8.54M 2025-12
Intrexon USD 1.02M 559K 2024-06
Ionis Pharmaceuticals USD 58.84M 15.16M 2026-06
Karyopharm Therapeutics USD 23.36M 2.82M 2026-03
Ligand Pharmaceuticals USD 54.8M 6.25M 2026-03
MacroGenics USD 10.42M 2.95M 2026-03
Neurocrine Biosciences USD 887M 118.9M 2026-06
Pfizer USD 16.19B 19M 2026-06
Regeneron Pharmaceuticals USD 6.57B 834.4M 2026-06
Rigel Pharmaceuticals USD 28.9M 1.39M 2024-06
Sangamo BioSciences USD 581K 110K 2024-06
Ultragenyx Pharmaceutical USD 60M 98M 2026-03
Veracyte USD 54.18M 4.06M 2026-06